Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2018; 39(04): 483-487
DOI: 10.4103/ijmpo.ijmpo_102_17
Original Article

Second Malignant Neoplasms in Children and Adolescents Treated for Blood Malignancies and Solid Tumors: A Single-Center Experience of 15 Years

Nikolaos Katzilakis
Department of Pediatric Hematology-Oncology, University Hospital of Heraklion, University of Crete, Heraklion
,
Maria Tsirigotaki
Department of Pediatric Hematology-Oncology, University Hospital of Heraklion, University of Crete, Heraklion
,
Maria Stratigaki
Department of Pediatric Hematology-Oncology, University Hospital of Heraklion, University of Crete, Heraklion
,
Eleni Kampouraki
Department of Pediatric Hematology-Oncology, University Hospital of Heraklion, University of Crete, Heraklion
,
Emmanouil Markaki Athanasopoulos
Department of Pediatric Hematology-Oncology, University Hospital of Heraklion, University of Crete, Heraklion
,
Athina Erasmia
Department of Pediatric Hematology-Oncology, University Hospital of Heraklion, University of Crete, Heraklion
,
Antonis Kattamis
Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Athens, Aghia Sofia Children’s Hospital, Athens, Greece
,
Eftichia Stiakaki
Department of Pediatric Hematology-Oncology, University Hospital of Heraklion, University of Crete, Heraklion
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

Context: The occurrence of second malignancies is not rare in children treated for primary tumors. Objectives: The aim of this study was to investigate the occurrence and the outcomes of second malignancies in children and adolescents from a large tertiary pediatric hematology-oncology center. Materials and Methods: A retrospective study was performed looking into the characteristics and outcomes of second malignant neoplasms in children and adolescents treated for primary malignancies in a single center over a 15-year period. Results: Among 270 children and adolescents treated for hematological malignancies and solid tumors from 2000 to 2015, five cases of second malignancy were diagnosed including cancer of the parotid gland, renal cell carcinoma, Hodgkin’s lymphoma, thyroid carcinoma, and transitional liver cell carcinoma in patients previously treated for acute myeloid leukemia, glioblastoma multiforme, B-acute lymphoblastic leukemia, Langerhans cell histiocytosis, and medulloblastoma, respectively. Primary malignancies were treated with chemotherapy in all cases and four out of five patients had also received radiotherapy. Mean age at diagnosis of second malignancy was 10 years and 4 months. Overall survival after diagnosis of second malignancy was 80% at 12 months and 75% at 5 years. Conclusions: Close surveillance and long-term follow-up are mandatory for the identification of late effects in children treated for malignancy.

Keywords

Childhood cancer - late effects - second malignant neoplasm


Publication History

Article published online:
17 June 2021

© 2018. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ng AK, Kenney LB, Gilbert ES, Travis LB. Secondary malignancies across the age spectrum. Semin Radiat Oncol 2010; 20: 67-78
    CrossrefPubMedGoogle Scholar
  • 2 Morton LM, Onel K, Curtis RE, Hungate EA, Armstrong GT. The rising incidence of second cancers: Patterns of occurrence and identification of risk factors for children and adults. Am Soc Clin Oncol Educ Book 2014:e57-67.
  • 3 Garaventa A, Gambini C, Villavecchia G, Di Cataldo A, Bertolazzi L, Pizzitola MR. et al. Second malignancies in children with neuroblastoma after combined treatment with 131I metaiodobenzylguanidine. Cancer 2003; 97: 1332-8
    CrossrefPubMedGoogle Scholar
  • 4 Duffner PK, Krischer JP, Horowitz ME, Cohen ME, Burger PC, Friedman HS. et al. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: A Pediatric Oncology Group study. Ann Neurol 1998; 44: 313-6
    CrossrefPubMedGoogle Scholar
  • 5 Vázquez E, Castellote A, Piqueras J, Ortuno P, Sánchez Toledo J, Nogués P. et al. Second malignancies in pediatric patients: Imaging findings and differential diagnosis. Radiographics 2003; 23: 1155-72
    CrossrefPubMedGoogle Scholar
  • 6 Moppett J, Oakhill A, Duncan AW. Second malignancies in children: The usual suspects?. Eur J Radiol 2001; 37: 95-108
    CrossrefPubMedGoogle Scholar
  • 7 Norkin M, Uberti JP, Schiffer CA. Very late recurrences of leukemia: Why does leukemia awake after many years of dormancy?. Leuk Res 2011; 35: 139-44
    CrossrefPubMedGoogle Scholar
  • 8 Maule M, Scélo G, Pastore G, Brennan P, Hemminki K, Tracey E. et al. Risk of second malignant neoplasms after childhood leukemia and lymphoma: An international study. J Natl Cancer Inst 2007; 99: 790-800
    CrossrefPubMedGoogle Scholar
  • 9 Leung W, Ribeiro RC, Hudson M, Tong X, Srivastava DK, Rubnitz JE. et al. Second malignancy after treatment of childhood acute myeloid leukemia. Leukemia 2001; 15: 41-5
    CrossrefPubMedGoogle Scholar
  • 10 Landier W, Armenian S, Bhatia S. Late effects of childhood cancer and its treatment. Pediatr Clin North Am 2015; 62: 275-300
    CrossrefPubMedGoogle Scholar
  • 11 Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M. et al. Subsequent neoplasms in 5 year survivors of childhood cancer: The Childhood Cancer Survivor Study. J Natl Cancer Inst 2010; 102: 1083 95
    CrossrefPubMedGoogle Scholar
  • 12 de Vathaire F, Scwhartz B, El Fayech C, Allodji RS, Escudier B, Hawkins M. et al. Risk of a second kidney carcinoma following childhood cancer: Role of chemotherapy and radiation dose to kidneys. J Urol 2015; 194: 1390-5
    CrossrefPubMedGoogle Scholar
  • 13 Nakano Y, Fujimaru R, Ishii K, Sakamoto H, Inoue T, Sako M. et al. Childhood pheochromocytoma in a survivor of central primitive neuroectodermal tumor. Pediatr Int 2013; 55: e100-2
    CrossrefPubMedGoogle Scholar
  • 14 Caglar K, Unal S, Cetinkaya A, Gümrük F, Yetgin S. Acute lymphoblastic leukemia as a second malignant neoplasm in a child with medulloblastoma. Pediatr Hematol Oncol 2003; 20: 535-7
    CrossrefPubMedGoogle Scholar
  • 15 Ragusa R, Russo S, Villari L, Schilirò G. Hodgkin’s disease as a second malignant neoplasm in childhood: Report of a case and review of the literature. Pediatr Hematol Oncol 2001; 18: 407-14
    CrossrefPubMedGoogle Scholar
  • 16 Geetha N, SreedeviAmma N, Kusumakumary P, Lali VS, Nair MK. Acute lymphoblastic leukemia occurring as a second malignancy: Report of a case and review of literature. Pediatr Hematol Oncol 1999; 16: 267-70
    CrossrefPubMedGoogle Scholar
  • 17 Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley BL. Sarcoma arising in irradiated bone; report of 11 cases. Cancer 1948; 1: 3-29
    CrossrefPubMedGoogle Scholar
  • 18 Schrantz JL, Araoz CA. Radiation induced meningeal fibrosarcoma. Arch Pathol 1972; 93: 26-31
    PubMedGoogle Scholar
  • 19 Zhang AY, Judson I, Benson C, Wunder JS, Ray-Coquard I, Grimer RJ. et al. Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study. Br J Cancer 2017; 25 (117) 326-31
    CrossrefPubMedGoogle Scholar
  • 20 Kunert P, Matyja E, Prokopienko M, Marchel A. Radiation induced tumours of meninges. Report on eight cases and review of the literature. Neurol Neurochir Pol 2012; 46: 542-52
    CrossrefPubMedGoogle Scholar
  • 21 Meadows AT, Friedman DL, Neglia JP, Mertens AC, Donaldson SS, Stovall M. et al. Second neoplasms in survivors of childhood cancer: Findings from the childhood cancer survivor study cohort. J Clin Oncol 2009; 27: 2356-62
    CrossrefPubMedGoogle Scholar
  • 22 Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J. et al. Minimal residual disease directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. Lancet Oncol 2010; 11: 543-52
    CrossrefPubMedGoogle Scholar
  • 23 Creutzig U, Zimmermann M, Dworzak MN, Ritter J, Schellong G, Reinhardt D. Development of a curative treatment within the AML BFM studies. Klin Padiatr 2013; 225 (01) Suppl S79-86
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Pession A, Masetti R, Rizzari C, Putti MC, Casale F, Fagioli F. et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood 2013; 122: 170-8
    CrossrefPubMedGoogle Scholar
  • 25 Prasannan L, Pu A, Hoff P, Weatherly R, Castle V. Parotid carcinoma as a second malignancy after treatment of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1999; 21: 535-8
    CrossrefPubMedGoogle Scholar
  • 26 Tikku G, Jain D, Kumari A, Grover R. Mucoepidermoid carcinoma of parotid as a second malignancy in acute lymphoblastic leukemia. Indian Pediatr 2015; 52: 979-80
    CrossrefPubMedGoogle Scholar
  • 27 Koh KN, Yoo KH, Im HJ, Sung KW, Koo HH, Kim HS. et al. Characteristics and outcomes of second malignant neoplasms after childhood cancer treatment: Multi center retrospective survey. J Korean Med Sci 2016; 31: 1254-61
    CrossrefPubMedGoogle Scholar
  • 28 Kraushaar G, Wiebe S. Renal cell carcinoma as a second malignant neoplasm in a patient with non syndromic hemihypertrophy and previous Wilms tumor. Pediatr Radiol 2005; 35: 1208-11
    CrossrefPubMedGoogle Scholar
  • 29 Lazarus J, Moolman C. Renal cell carcinoma as second malignancy in patient with previous Wilms tumor. Urology 2009; 74: 598-600
    CrossrefPubMedGoogle Scholar
  • 30 Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M. et al. Second malignant neoplasms in five year survivors of childhood cancer: Childhood cancer survivor study. J Natl Cancer Inst 2001; 93: 618-29
    CrossrefPubMedGoogle Scholar
  • 31 Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H. et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li Fraumeni syndrome: 11 year follow up of a prospective observational study. Lancet Oncol 2016; 17: 1295-305
    CrossrefPubMedGoogle Scholar
  • 32 Guarino S, Giusti DM, Rubini A, Favoriti P, Fioravanti C, Di Matteo FM. et al. Association between pituitary langerhans cell histiocytosis and papillary thyroid carcinoma. Clin Med Insights Case Rep 2013; 6: 197-200
    CrossrefPubMedGoogle Scholar
  • 33 Jamaati HR, Shadmehr MB, Saidi B, Khosravi A, Arab M, Mohammadi F. Langerhans cell histiocytosis of the lung and thyroid, co existing with papillary thyroid cancer. Endocr Pathol 2009; 20: 133-6
    CrossrefPubMedGoogle Scholar
  • 34 Patten DK, Wani Z, Tolley N. Solitary langerhans histiocytosis of the thyroid gland: A case report and literature review. Head Neck Pathol 2012; 6: 279-89
    CrossrefPubMedGoogle Scholar
  • 35 Moschovi M, Adamaki M, Vlahopoulos S, Rodriguez Galindo C. Synchronous and metachronous thyroid cancer in relation to Langerhans cell histiocytosis; involvement of V600E BRAF mutation?. Pediatr Blood Cancer 2015; 62: 173-4
    CrossrefPubMedGoogle Scholar
  • 36 Goldstein AM, Yuen J, Tucker MA. Second cancers after medulloblastoma: Population based results from the United States and Sweden. Cancer Causes Control 1997; 8: 865-71
    CrossrefPubMedGoogle Scholar
  • 37 Milde T, Oehme I, Korshunov A, Kopp Schneider A, Remke M, Northcott P. et al. HDAC5 and HDAC9 in medulloblastoma: Novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res 2010; 16: 3240-52
    CrossrefPubMedGoogle Scholar
  • 38 Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: Results of Children’s Oncology Group trial A 9961. Neuro Oncol 2013; 15: 97-103
    CrossrefPubMedGoogle Scholar
  • 39 Nomura Y, Yasumoto S, Yanai F, Akiyoshi H, Inoue T, Nibu K. et al. Survival and late effects on development of patients with infantile brain tumor. Pediatr Int 2009; 51: 337-41
    CrossrefPubMedGoogle Scholar
  • 40 Lau CS, Mahendraraj K, Chamberlain RS. Hepatocellular carcinoma in the pediatric population: A population based clinical outcomes study involving 257 patients from the surveillance, epidemiology, and end result (SEER) database (1973 2011). HPB Surg 2015; 2015: 670728
    PubMedGoogle Scholar
  • 41 Ozcan HN, Oguz B, Salim T, Talim B, Haliloglu M. A rare malignant hepatic tumor of childhood: Transitional liver cell tumor revisited. JBR-BTR 2015; 98: 79-81
    PubMedGoogle Scholar
  • 42 Goyal S, Singh RR, Balukrishna S, Bindra M, Backianathan S. An early and rare second malignancy in a treated glioblastoma multiforme: Is it radiation or temozolomide?. J Clin Diagn Res 2015; 9: TD05-7
    PubMedGoogle Scholar